Prostate cancer is the second most common malignancy in men, contributing significantly to male mortality rates. Approximately 13% of men will be diagnosed with prostate cancer at some point during their lifetime. There are approximately 65,000 drug-treatable mCRPC cases in the U.S. annually. The 5-year survival in mCRPC is approximately 30%.1
When prostate cancer spreads beyond the prostate gland, it is considered metastatic, meaning it has grown into nearby organs or tissues. mCRPC is an advanced form of the disease that continues to progress, indicated by signs such as rising prostate-specific antigen (PSA), even when testosterone levels are low.
In mCRPC, the cancer stops responding to hormone treatments and can become life-threatening if it spreads to areas such as the lymph nodes, bones, the bladder, rectum, liver, lungs, and other organs. Most prostate cancer-related deaths are the result of mCRPC. Historically the median survival for men with mCRPC has been less than two years.2
While multiple treatment options now exist for non-metastatic castration-resistant prostate cancer, mCRPC remains an incurable disease and represents a critical area of unmet medical need.
References:
1. Seer.cancer.gov https://seer.cancer.gov/statfacts/html/prost.html
2. Lowrance, et al. Journal of Urology, 2018 Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018.
